U.S. IV Therapy Market Report 2026: 1,305 Clinics, Drip Menu Trends, Regulation

Last updated: May 2026

TL;DR — U.S. IV Therapy Market Report 2026

• 1,305 U.S. IV therapy clinics indexed; California (30), Texas (28), Florida (22), New York (14), and Pennsylvania (12) lead the named-state count.
• 1,053 of 1,055 clinics that publish pricing fall in the $$ tier ($100-$400/session); concierge $$$ pricing is rare (2 clinics).
• Most "drip menu" ingredients are compounded under FDA Section 503A; FDA does not review them for safety or efficacy.
• Evidence base is thin: the Ali 2009 Myers' Cocktail RCT was null vs placebo, and NAD+ IV human data is limited to small pilot studies.

State of the U.S. IV therapy market in 2026

The U.S. IV therapy market in 2026 spans at least 1,305 clinics in our directory, with California, Texas, Florida, New York, and Pennsylvania holding the largest named-state clusters. The category sits inside a global IV vitamin therapy market that one industry analyst values at $4.2 billion in 2025 and projects will reach $8.1 billion by 2032 — a 10.2% CAGR.

Demand is bifurcated. Hospital infusion centers handle the bulk of medically necessary IV therapy — dehydration from gastroenteritis, chemotherapy support, total parenteral nutrition — while cash-pay drip bars and mobile IV operators drive nearly all the new-clinic count. A separate forecast pegs the IV therapy membership sub-market at $1.94 billion in 2025 growing 11.2% annually, a sign that the category has shifted from one-off recovery visits to subscription-style wellness.

The clinic format is shifting too. Mobile IV providers — registered nurses dispatched to homes, hotels, and offices — now compete head-on with brick-and-mortar drip bars on price and convenience. Our directory shows mobile-first operators scattered across at least 20 states, though their state assignment is often blank in scraped data because they list a service area rather than a single address.

That coverage gap matters. Of the 1,305 records in our index, 1,075 (82%) currently lack a verified U.S. state. Most are mobile concierge operators or franchise-owned drip bars whose Google Maps listing shows a service radius rather than a fixed street address. We resolve these through quarterly Outscraper refreshes and manual verification.

Three forces are reshaping U.S. IV therapy demand in 2026. First, franchise consolidation is accelerating — The DRIPBaR reports 600+ locations in development, and Hydrate IV Bar has claimed 26 of 47 available U.S. territories. Second, Restore Hyper Wellness — once the largest single chain offering IV alongside cryotherapy and red-light — restructured through bankruptcy in 2024 with 18 franchises permanently closed, and now operates roughly 209 studios. Third, the FDA's January 2025 final interim guidance on bulk drug substances tightens which ingredients 503A pharmacies can compound — pulling the rug out from under any drip recipe that depends on non-USP ingredients.

The regulatory backdrop is also state-by-state. California requires medical-corporation ownership and direct RN supervision by a physician, PA, or NP. New York demands 100% physician ownership of any IV practice. Texas restricts ownership to physicians and bars non-physician investors. These ownership rules matter for any operator trying to scale a chain across state lines.

Drip menu trends in 2026

The U.S. drip menu has standardized around five recipes: hydration (plain saline or LR), Myers' Cocktail, NAD+, glutathione, and custom "performance" blends. Most clinics publish all five plus a hangover and immunity variant. The differences between menus are usually dosage and which sterile-injectable additives the compounding pharmacy supplies.

Hydration is the loss-leader — typically $99-$150 for a bag of 0.9% normal saline or lactated Ringer's, sometimes with B-complex and electrolytes. It is the only drip on most menus that is medically uncontroversial, since IV crystalloid hydration has been standard hospital care for decades.

Myers' Cocktail — magnesium, calcium, B-complex, B5, B6, B12, and vitamin C — anchors most menus at $179-$300. It is the recipe most associated with Dr. John Myers, the Baltimore physician who popularized IV micronutrient therapy in the 1970s. Despite its ubiquity, the evidence base is thin (see below).

NAD+ is the premium ticket. The standard IV dose ranges from 250 mg to 1,000 mg per session, priced at $400-$1,500. Some longevity clinics push 2,000 mg "loading doses" at $2,000+, though there is no clinical consensus on optimal dosing. NAD+ infusions take 2-4 hours because faster delivery causes nausea and flushing.

Glutathione typically appears as a standalone push ($75-$150) or as an add-on to hydration or Myers' ($25-$50). It is most often marketed for skin brightening and antioxidant support, neither of which has robust RCT evidence in healthy adults.

Custom or "performance" drips bundle vitamin C, taurine, amino acids, magnesium, and B-complex at $200-$450. These vary the most between clinics and are also where compounding-pharmacy supply chain disruption hits hardest.

Comparison table: U.S. drip types in 2026

Avg $ reflects the midpoint of published session prices across the 1,055 clinics in our directory that publish pricing as of May 2026. Concierge clinics ($$$ tier) skew higher.

State distribution — top 25

The 230 clinics in our index with a confirmed U.S. state cluster heavily in California (30), Texas (28), Florida (22), New York (14), and Pennsylvania (12). These five states account for roughly 46% of all clinics where we have verified state assignment.

Per-capita density paints a different picture. South Carolina (7 clinics, ~5.4 million population) and Rhode Island (2 clinics, ~1.1 million) punch above their weight, driven by integrative-medicine concentration in Charleston, Mt Pleasant, and Providence. Idaho, Montana, and New Mexico each have 2 clinics and a small base — the long tail of the U.S. IV market.

A separate 1,075 records in our master index don't yet have a confirmed state assignment and are excluded from the table above. They feed quarterly verification queues — see Methodology.

Pricing landscape

U.S. IV therapy session prices in 2026 cluster tightly in the $100-$400 range, with NAD+ and concierge longevity clinics pushing the ceiling to $1,500+. Our directory captures 1,055 clinics with published price tiers; 1,053 (99.8%) sit in the $$ tier and just 2 in the $$$ tier.

The distribution is roughly:

• $$ tier ($100-$400/session): 1,053 clinics (80.7% of all records, 99.8% of priced records) — dominated by drip bars, mobile IV operators, and integrative-medicine practices.
• $$$ tier ($400+/session): 2 clinics — concierge longevity practices like NextHealth and metabolic-optimization boutiques.
• No published price: 250 clinics (19.2%) — typical of medical spas that quote on intake or hospital infusion centers that bill insurance.

The narrow $ vs $$$ split is structural. Almost every U.S. drip is compounded by 503A pharmacies, the cost of saline + B-vitamins + ascorbic acid is low, and the labor (one RN + a 60-minute room turn) doesn't vary much across markets. That keeps base prices in a tight band.

NAD+ is the lone exception. Because NAD+ raw material is expensive ($150-$400 per 500 mg dose at compounding-pharmacy wholesale), session prices scale linearly with dosage. A 250 mg "starter" runs $300-$450; a 1,000 mg session runs $1,000-$1,500.

For self-pay patients on a multi-session protocol, the dominant cost lever is the membership model. Hydrate IV Bar membership ($75-$125/month) and Restore's Hyper Pass typically include 1-2 drips per month at a 25-40% discount vs walk-in. Annual unlimited memberships at biohacker-style clinics range from $2,400 to $7,200 depending on whether NAD+ is included.

Geographic pricing variation

Urban-metro pricing varies meaningfully. Manhattan, San Francisco, and Boston cash-pay clinics regularly quote $250-$350 for a Myers' Cocktail and $1,200-$1,800 for NAD+. Cash-pay clinics in lower-cost states (Idaho, Tennessee, Kentucky) frequently quote $159-$199 for Myers' and $600-$900 for NAD+. Florida and Arizona, both heavy on retiree wellness traffic, sit in the middle.

For deeper city-level breakdowns, see Best IV Therapy in Los Angeles, New York, and Chicago: 2026 Guide and Best IV Therapy in Philadelphia, San Diego, and Minneapolis: 2026 Guide.

Regulatory framework

The U.S. IV therapy regulatory framework is layered. The FDA governs the drugs and additives via Section 503A compounding rules. State medical and nursing boards govern who can administer IV therapy and under whose supervision. State pharmacy boards license the compounding pharmacies that supply most drip ingredients.

FDA Section 503A compounding

Most drip-bar ingredients — B-complex, magnesium, calcium, glutathione, NAD+, methylcobalamin — are not FDA-approved drug products. They are compounded by state-licensed 503A pharmacies under Section 503A of the Federal Food, Drug, and Cosmetic Act. The FDA explicitly states it does not review compounded drugs for safety, efficacy, or quality.

Section 503A compounding requires that the bulk drug substance either comply with an applicable USP/NF monograph, be a component of an FDA-approved drug product, or appear on the FDA's 503A bulks list. The FDA's January 2025 interim guidance ends the "Category 1" pathway for newly nominated bulk substances — pharmacies can no longer compound with newly proposed ingredients until FDA review is complete.

Larger 503B outsourcing facilities (registered with FDA, subject to CGMP) supply some hospital infusion centers but rarely serve cash-pay drip bars. The clinic-by-clinic mix of 503A vs 503B sourcing is not publicly disclosed, which is one of the structural opacity problems in this market.

State medical/nursing board rules

Every state requires a "good-faith examination" before any IV therapy — performed by a physician, PA, or NP. After that initial assessment, registered nurses can administer IV therapy in most states without the prescribing physician physically present.

The three largest states diverge on ownership and supervision. California's Business and Professions Code requires that any medical corporation offering IV therapy be majority-owned (51%+) by a licensed physician. The Board of Registered Nursing requires RNs to administer IV therapy under physician supervision and explicitly prohibits medical assistants from starting IVs.

New York is stricter. New York demands 100% physician ownership of any IV practice and requires direct supervision by a physician, PA, NP, or RN for any LPN delivering IV therapy.

The Texas Medical Board limits IV-clinic ownership to licensed physicians and requires the physician to maintain a collaborative practice relationship with each RN delivering IV therapy.

Mobile IV rules

Mobile IV operators — RNs dispatched to homes, hotels, and offices — must comply with the same good-faith-exam and physician-oversight rules as brick-and-mortar clinics. The wrinkle: the supervising physician must be licensed in the state where the patient receives the IV, which constrains how mobile chains expand across state lines.

A handful of states (Florida, Texas, Arizona) have relatively permissive mobile IV environments. Others (New York, California, New Jersey) impose tight licensing reviews on mobile operators. The FDA does not regulate mobile delivery itself — that's a state matter — but it does regulate the ingredients in the bag.

Evidence base by drip type

The clinical evidence supporting most U.S. drip recipes is thin. Below is an honest, citation-by-citation summary of what each major drip type has actually been tested for in humans.

Myers' Cocktail

The Myers' Cocktail recipe is widely administered but has only one published placebo-controlled RCT. The Ali et al. 2009 trial at Yale randomized 34 fibromyalgia patients to weekly Myers' Cocktail vs placebo for 8 weeks. Both arms improved on tender points, pain, depression, and quality of life — but the study found "no statistically significant benefit over placebo." That is the entire RCT evidence base for the Myers' Cocktail in 2026.

Smaller open-label studies suggest possible benefit for tension headache and asthma, but none are placebo-controlled. Patients who report feeling better after Myers' may be experiencing genuine benefit, placebo response, or simple IV-saline hydration — the trial cannot distinguish.

NAD+

The IV NAD+ evidence base is even thinner. The Grant et al. 2019 pilot study infused 750 mg of NAD+ over 6 hours in 8 male participants and confirmed that plasma NAD+ rises during infusion and that the infusion is tolerated without adverse events. That is a pharmacokinetic study, not an efficacy trial.

The more recent Niagen IV vs NAD+ IV pilot RCT (medRxiv preprint, 2024) compared 500 mg NR IV, 500 mg NAD+ IV, oral NR, and saline IV in healthy adults. The trial found NR IV was safer and faster to infuse than NAD+ IV but did not establish clinical efficacy for any outcome. A separate retrospective real-world pilot compared tolerability of NAD+ vs NR IV in clinic settings.

No large RCT has established that IV NAD+ delivers a clinical benefit for aging, addiction, or chronic fatigue — the three indications most aggressively marketed. The infusion itself is generally safe; the efficacy case is unproven.

Glutathione

The IV glutathione evidence is mixed and limited. The Hauser et al. 2009 double-blind pilot RCT tested 1,400 mg IV glutathione three times a week for 4 weeks in 21 Parkinson's patients with motor symptoms. The therapy was safe and well tolerated but did not show a statistically significant benefit over placebo on the primary motor outcome.

A later systematic narrative review of IV glutathione for Parkinson's noted that one trial of 1,200 mg/day showed motor improvement, while a follow-on trial at 700 mg/day did not. The reviewers concluded that adequately powered RCTs are still needed.

For skin lightening and antioxidant support — the two largest cash-pay marketing claims — there are no high-quality U.S. RCTs. The 2019 FDA-warned injectable vitamin product cases underscore the safety risk of unapproved injectables more broadly.

High-dose vitamin C

High-dose IV vitamin C (10-100 g per infusion) has a deeper research base than the cocktail drips. The NIH Office of Dietary Supplements vitamin C fact sheet summarizes the evidence for cancer adjunct and sepsis. ODS describes the cancer-adjunct trial results as "mixed" and emphasizes that high-dose IV ascorbate is classified as a drug (not a supplement) in the U.S.

ODS also notes that doses up to 1,500 mg/kg have been safely administered to healthy volunteers and cancer patients, though G6PD-deficient patients face hemolysis risk and must be screened before infusion. Most drip-bar Myers' Cocktail vitamin C doses (5-10 g) are well below the oncology research range.

Hydration

Plain IV saline or lactated Ringer's is the only drip on most U.S. menus with unequivocal medical evidence. IV crystalloid hydration has been standard hospital care for severe dehydration, gastroenteritis, heat illness, and acute alcohol poisoning for decades. For mild dehydration in healthy adults, oral rehydration is equally effective at a fraction of the cost.

Major chains in 2026

The U.S. IV therapy chain landscape consolidated in 2024 after Restore Hyper Wellness's bankruptcy restructuring. Four operators now define national-scale IV therapy: Restore, Hydrate IV Bar, The DRIPBaR, and NextHealth.

Restore Hyper Wellness operates roughly 209-230 studios across 40+ states, offering IV alongside cryotherapy, red-light therapy, and HBOT. The 2024 bankruptcy resulted in 18 franchise closures but the brand survived as a going concern. Its menu spans hydration ($129), Myers' ($229), and NAD+ ($349-$1,200) with a Hyper Pass membership.

The DRIPBaR leads the category by location pipeline, with 600+ franchises in development and a 2024 partnership with REVIV (the global IV operator with 2 million+ treatments across 40+ countries). The DRIPBaR menu emphasizes NAD+ and a tiered membership model.

Hydrate IV Bar is a smaller but faster-scaling operator concentrated in Colorado, Arizona, Texas, and Utah. It reports 90,000+ clients served and 10,000+ memberships sold. Its growth strategy is a membership-first model that targets 40%+ recurring revenue from day one.

NextHealth, a Los Angeles-based concierge longevity clinic, anchors the $$$ tier with IV drips bundled into broader longevity-medicine packages (genetic testing, hormone optimization, peptides). Most NextHealth members pay $5,000-$15,000 per year for the full package; standalone IV sessions run $300-$1,500+.

For the best directly comparable drip-bar economics, see our Best IV Therapy Memberships of 2026 Cost-Per-Drip Comparison.

How to verify a clinic

Before booking IV therapy, three checks separate well-run clinics from sketchy operations.

First, verify the RN credential. Every IV must be started by a licensed registered nurse (or NP, PA, or physician — never a medical assistant). Ask which state licenses the RN, and look up the license number on the state nursing board's website. California's BRN, Texas's BON, and New York's Office of the Professions all offer free license lookup.

Second, verify the medical director. Every U.S. IV clinic must have a physician medical director who has signed off on the protocols. Ask for the medical director's name and verify their license on the state medical board's website. If the clinic can't or won't name their medical director, that is a red flag.

Third, verify the compounding pharmacy. Ask which pharmacy supplies the drip ingredients and whether it is a 503A (state-licensed) or 503B (FDA-registered outsourcing facility) pharmacy. 503B-sourced ingredients carry CGMP-level quality assurance; 503A ingredients carry only state-level oversight. Either can be safe, but you have the right to know which is supplying what's going into your vein.

Red flags to walk away from include: clinics that won't disclose ingredient sources, clinics that allow medical assistants to start IVs, clinics that quote "miracle cure" claims for serious conditions like cancer, autism, or Lyme disease, and mobile operators who can't produce a physician oversight agreement on request.

For deeper credentialing context, see Cheapest Mobile IV Services Under $150 and Myers Cocktail in 2026: Pricing and Top Providers.

FAQ

How many IV therapy clinics are there in the U.S. in 2026?

Our directory indexes 1,305 U.S. IV therapy clinics as of May 2026. Of those, 230 have a verified U.S. state — California (30), Texas (28), Florida (22), New York (14), and Pennsylvania (12) lead. The remaining 1,075 are largely mobile concierge operators and franchise locations whose state assignment is still in verification.

Is IV vitamin therapy FDA-approved?

No. The individual ingredients (B-complex, magnesium, glutathione, NAD+, vitamin C) are compounded under FDA Section 503A, which means FDA does not review them for safety, effectiveness, or quality. The FDA approves the underlying drug substance only when it is an active pharmaceutical ingredient in an FDA-approved drug — most drip ingredients are not.

How much does IV therapy cost in 2026?

Most U.S. IV therapy sessions run $100-$400. Hydration drips average $99-$150, Myers' Cocktail $179-$300, glutathione push $75-$150, and NAD+ $400-$1,500 depending on dosage. Concierge longevity clinics like NextHealth can run $1,500+ per session.

Does insurance cover IV therapy?

Generally no. Almost all cash-pay drip-bar IV therapy is considered medically unnecessary by insurers. Hospital-based IV therapy for genuine medical indications (severe dehydration, chemotherapy support, TPN) is covered by Medicare and commercial insurance under standard infusion-therapy CPT codes.

Is the Myers' Cocktail clinically proven?

No. The only placebo-controlled RCT of the Myers' Cocktail — Ali et al. 2009 at Yale — found no statistically significant benefit over placebo in fibromyalgia patients. Open-label studies suggest possible benefit for tension headache and asthma but are not placebo-controlled.

Is NAD+ IV therapy safe?

The Grant et al. 2019 pilot study infused 750 mg of NAD+ over 6 hours in 8 healthy male participants with no adverse events. The 2024 Niagen IV pilot RCT found 500 mg NR IV was safer and faster to infuse than NAD+ IV. Both studies suggest acute safety at clinical doses, but long-term safety and efficacy remain unproven.

Who can legally start an IV in the U.S.?

Registered nurses, nurse practitioners, physician assistants, and physicians can administer IV therapy in all 50 states. Medical assistants cannot start IVs in most states. Every IV must be preceded by a good-faith medical examination performed by a physician, NP, or PA. State-by-state rules vary on ownership, supervision, and mobile delivery.

What are the largest IV therapy chains?

Restore Hyper Wellness (209-230 studios), The DRIPBaR (600+ in development), and Hydrate IV Bar (90,000+ clients served) lead by location count. Concierge operators like NextHealth lead by per-session price. The DRIPBaR partnered with REVIV in 2024 to expand internationally.

How do I verify a clinic before booking?

Ask for the RN's license number and look it up on the state nursing board's site. Ask for the medical director's name and verify their physician license. Ask which compounding pharmacy supplies the drip ingredients (503A vs 503B). Walk away from any clinic that won't disclose all three.

Methodology

The 1,305 clinic count comes from our proprietary IV therapy directory, last refreshed May 2026. Sources include Outscraper scrapes of Google Maps "IV therapy near me" results across the 50 largest U.S. metros, manual verification of franchise location lists from Restore, Hydrate, and The DRIPBaR, and submissions from clinic operators.

State assignment is derived from the clinic's Google Maps verified address. Mobile concierge operators that list a service radius rather than a fixed address show up as "unknown" state until manual verification confirms a primary operating address. 82% of our records currently lack verified state assignment for that reason; coverage improves quarterly.

Price tier ($, $$, $$$) is based on the clinic's published menu price for a standard Myers' Cocktail or equivalent drip. $$ = $100-$400 per session; $$$ = $400+ per session. 250 clinics in our index have no published price (typically because they quote on intake or bill insurance directly).

Drip-type evidence ratings draw on PubMed-indexed RCTs, the NIH Office of Dietary Supplements, FDA guidance documents, and peer-reviewed systematic reviews. Where evidence is weak or null, we say so plainly. We do not make therapeutic claims beyond what the cited primary sources support.

Inaccuracies can be reported to corrections@ivtherapymap.com. We refresh the master index quarterly and aim to resolve confirmed inaccuracies within 30 days.

Related reading

• Best IV Therapy Memberships of 2026 Cost-Per-Drip Comparison
• Myers Cocktail in 2026: Pricing and Top Providers
• Cheapest Mobile IV Services Under $150
• Best IV Therapy in Los Angeles, New York, and Chicago: 2026 Guide
• Best IV Therapy in Pennsylvania: 2026 Guide

This report is for informational purposes only and is not medical advice. IV therapy is a medical procedure that carries risks including infection, vein injury, allergic reaction, and electrolyte imbalance. Consult a licensed physician before starting any IV therapy regimen, particularly if you have kidney disease, heart failure, G6PD deficiency, or are pregnant. The U.S. FDA does not review compounded drip ingredients for safety or efficacy.

-- The IV Therapy Finder Team